Finally, although the trial is still recruiting, [68Ga]Ga-PSMA-11 has also been compared with [18F]F-DOPA in the PAraDiGM trial to differentiate GBM recurrence from TRC, showing a good performance of [68Ga]Ga-PSMA-11 in the preliminary results in nine patients [49]. Here, FOLH1 is linked to glioblastoma.